We have generated a human 293-derived retroviral packaging cell line (293GPG) capable of producing high titers of recombinant Moloney murine leukemia virus particles that have incorporated the vesicular stomatitis virus G (VSV-G) protein. To achieve expression of the retroviral gag-pol polyprotein, the precise coding sequences for gag-pol were introduced into a vector which utilizes totally nonretroviral signals for gene expression. Because constitutive expression of the VSV-G protein is toxic in 293 cells, we used the tetR/VP 16 transactivator and tet°minimal promoter system for inducible, tetracycline-regulatable expression of VSV-G. After stable transfection of the 293GPG packaging cell line with the MFG.SnlsLacZ retroviral vector construct, it was possible to readily isolate stable virus-producing cell lines with titers approaching 107 colony-forming units/ml. Transient transfection of 293GPG cells using a modified version of MFG.SnlsLacZ, in which the cytomegalovirus IE promoter was used to drive transcription of the proviral genome, led to titers of _106 colony-forming units/ml. The retroviral/VSV-G pseudotypes generated using 293GPG cells were significantly more resistant to human complement than commonly used amphotropic vectors and could be highly concentrated (>1000-fold). This new packaging cell line may prove to be particularly useful for assessing the potential use of retroviral vectors for direct in vivo gene transfer. The design of the cell line also provides at least theoretical advantages over existing cell lines with regard to the possible release of replicationcompetent virus. the VSV-G protein, since the constitutive expression of significant levels of VSV-G in most cells is toxic. However, this method of virus production significantly limits the evaluation of the potential applications of the viral pseudotypes, since only small amounts of virus can be easily produced. To overcome these difficulties, we have generated a stable humanderived cell line which constitutively expresses the necessary retroviral proteins for packaging and provides for large amounts of the VSV-G protein by inducible expression. We describe here the manner in which the cell line was constructed and some of the characteristics of the virus that is generated from the cells.
Currently, retroviral-mediated gene transfer is widely utilized to obtain efficient transduction of mammalian cells in vitro, and to date, has been the gene transfer method of choice for clinical protocols aimed at the evaluation of ex vivo strategies for gene therapy (1) . While standard murine-based retroviral vectors are well suited for use in such ex vivo applications, the vectors have found only limited use in strategies involving direct in vivo gene transfer (1) . One major limitation of the commonly used vector/packaging cell systems is the inability to easily purify and concentrate the large amounts of virus often needed for direct in vivo gene transfer applications. A second limitation relates to the sensitivity of virus with amphotropic host range to inactivation by human serum (2) (3) (4) . A final limitation of all murine-based vectors is their inability to integrate in quiescent cells (5, 6) .
One recent advance that may prove to be important for the eventual use of retrovirus vectors for direct in vivo gene transfer was the demonstration that it is possible to generate retrovirus vector particles which have incorporated the vesicular stomatitis virus G (VSV-G) protein (7) . The resulting VSV-G/retroviral pseudotypes possessed the wide host range of VSV and could be highly concentrated without loss of biological activity (8) . This finding follows very early studies which had demonstrated the capacity of retroviruses and VSV to form viral pseudotypes upon coinfection of cells with both viruses (9) . In the recent work, the procedure used to generate virus involved the use of transient transfection techniques to express the VSV-G protein, since the constitutive expression of significant levels of VSV-G in most cells is toxic. However, this method of virus production significantly limits the evaluation of the potential applications of the viral pseudotypes, since only small amounts of virus can be easily produced. To overcome these difficulties, we have generated a stable humanderived cell line which constitutively expresses the necessary retroviral proteins for packaging and provides for large amounts of the VSV-G protein by inducible expression. We describe here the manner in which the cell line was constructed and some of the characteristics of the virus that is generated from the cells.
MATERIALS AND METHODS
Cell Lines and Drug Selections. Adenovirus 5-transformed human embryonic kidney 293 cells (10) were obtained from B. Panning (Whitehead Institute). The 293 cells were grown in 293 growth medium containing Dulbecco's modified eagle medium (DMEM) (GIBCO/BRL), 10% (vol/vol) inactivated fetal bovine serum (IFS) (Sigma), 2 mM L-glutamine (GIBCO/BRL), and 50 units/ml penicillin and streptomycin (GIBCO/BRL). Drug selections in transfected 293 cells were performed at 2 ,ug/ml puromycin (Sigma), 0.3 mg/ml G418 (GIBCO/BRL) and 100 jig/ml Zeocin (Invitrogen). All growth media, except where noted, was supplemented with 1 ,ug/ml tetracycline. NIH 3T3 cells (ATCC CRL 1658) were grown in DMEM containing 10% (vol/vol) calf serum (Sigma), and 50 units/ml penicillin and streptomycin. Mus dunni cells were grown in DMEM containing 5% (vol/vol) calf serum (Sigma), and 50 units/ml penicillin and streptomycin.
Proc. Natl. Acad. Sci. USA 93 (1996) 11401 Plasmid Constructs. The plasmid pBC.tTA (see Fig. 1 ) was constructed from pBC12/cytomegalovirus (CMV)/interleukin 2 (11) by replacement of the interleukin 2 sequences (bp 756-1439) with the tet transctivator gene from pUHD10-1 (12) . To construct pMDtet.G (Fig. 1) , the 1.6-kb EcoRI fragment from pSVGL (13) containing the VSV-G gene was cloned into the EcoRI cloning site in pMD.tet which is within exon 3 of the genomic human B3-globin sequence. pMDtet was constructed with a 0.47-kb XhoI-BamHI fragment from pUHC 13-3 (12) , which contains the tet operator and minimal human cytomegalovirus (HCMV) enhancer-promoter sequences, a 1.34-kb BamHI-XbaI fragment from pUCMd,3s(R)S (14) that includes the genomic human 3-globin sequences from the BamHI site in exon 2 through 690 bp in the 3' untranslated region, and a 3.06-kb XbaI-XhoI fragment from pSL301 (Invitrogen).
To construct pMD.gagpol (see Fig. 1 ), PCR was performed with pCRIPenv-(15) using the following pairs of primers: 5'-CGGAATTCATGGGCCAGACTGTTACC-3' and 5'-AGCAACTGGCGATAGTGG-3 ', 5 '-CGGAATTCT-TAGGGGGCCTCGCGG-3' and 5'-ACTACATGCTGAAC-CGGG-3'. The PCR products were digested with EcoRI and XhoI and with EcoRI and HindIll, respectively, to generate 0.94-kb EcoRI-XhoI and 0.94-kb HindIII-EcoRI fragments. These fragments were ligated with the 3.3-kb XhoI-HindIII fragment from pCRIPenv-and with pUC19, which had been linearized with EcoRI and calf intestinal phosphatase treated, to produce pUC19.gagpol. The 5.2-kb EcoRI fragment from pUC19.gagpol was cloned into the EcoRI cloning site in pMD to yield pMD.gagpol. pMD was constructed with the 3.1-kb EcoRI-BamHI fragment from pBC12/CMV/interleukin 2 that includes the pXF3 backbone and HCMV enhancerpromoter region and the previously described 1.34-kb BamHIXbaI fragment derived from pUCMd,Bs(R)S. The 3.1-kb EcoRI-BamHI and 1.34-kb BamHI-XbaI fragments were ligated after the EcoRI and XbaI overhangs were blunt-ended by Klenow treatment.
The plasmids pJ6fQpuro and pJ6fQbleo conferring resistance to puromycin and bleomycin (and zeocin), respectively, were kindly provided by J. Morgenstern (16) . The plasmid pSV2neo confers resistance to G418 (17) .
Retroviral Vectors. MFG.SnlsLacZ (see Fig. 1 ) was kindly provided by 0. Danos (18) . This vector is a derivative of MFG (19) in which mutations have been introduced at nucleotides 412 (A to T), 429 (T to A), and 631 (C to T) [nucleotide 625 of the Moloney murine leukemia virus (MuMLV) sequence]. These substitutions produce the sequence, ATGGGC-CCGGGGTAG, thereby preventing expression of the Nterminal portion of gag that would otherwise be expressed by the vector. The AU3nlslLacZ retroviral vector was constructed by precise replacement of the U3 region in the 5' long-terminal repeat of MFG.SnlsLacZ with the HCMV enhancer-promotor (bp -671 to -2) (20) . For the construction of AU3nlsLacZ, a 701-bp fragment encoding the HCMV promoter was generated by PCR with the pMD plasmid as the template with the pair of primers, 5'-GGGCCCAAGCTTCCCATTGCAT-ACGTTGTATC-3' and 5'-GGACTGGCGCCGGTTCAC-TAAACGAGCTC-3', creating a 5' HindIII site and a 3' KasI site. The PCR product was digested with HindIII and KasI to yield a 677-bp fragment. The 91-bp KasI-StyI was isolated from the 3' long-terminal repeat of MFG (19 ml 293GPG media the night before transfection. The media was changed 9 h posttransfection. The transfected 293GPG cells were plated by limiting dilution 48 h posttransfection in 293GPG media supplemented with zeocin and independent clones were isolated.
Transient transfections with 293GPG cells were performed on 60-mm dishes where 4-5 x 106 cells were plated the night before in 4 ml 293 growth medium. Four micrograms of AU3nlsLacZ was diluted into 300 ,l OptiMEM (GIBCO/ BRL) and incubated at room temperature for 30 min with 25 ,ul lipofectamine (GIBCO/BRL) diluted into 300 Al Opti-MEM. The DNA-lipofectamine mixture was diluted into 2.4 ml OptiMEM and layered on-top of the 293GPG cells, which had been rinsed 30 min before transfection and had media replaced with 2 ml OptiMEM. Seven to 8 h posttransfection, 2 ml 293 media was added, and the media was changed at 24 h with 2.5 ml 293 media. The supernatant was harvested at 72 h and viral titers determined as described below.
Analysis of VSV-G Expression in Transfected Cells. The pMDtet.G and pBC.tTA cotransfected clones were screened for inducible VSV-G expression by plating each clone in parallel into two 35-mm tissue culture dishes at 50% confluence. The following day one plate was rinsed twice with 2 ml 293G media without tetracycline and maintained in this media. At 48 h the postnuclear cellular lysates were prepared and the paired samples run on a 7.5% SDS/PAGE under reducing conditions. The gels were transferred onto nitrocellulose (0.45 mm; Schleicher & Schuell) with a semidry electroblotter (Owl Scientific, Woburn, MA). Western blot analysis was performed by using a murine monoclonal anti-VSV-G IgG (Sigma) at a dilution of 1:800 and a peroxidase-conjugated F(ab')2 fragment donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories) was used at a dilution of 1:10,000. Detection by chemiluminescence was performed using commercially available reagents (Renaissance; New England Nuclear). Assays For Reverse Transcriptase (RT) and 18-Galactosidase Activity. 293G cells transfected with pMD.gagpol were screened for RT activity in the culture medium of subconfluent clones growing in 24-well culture dishes as described (24) . Cells were stained for B3-galactosidase activity as described (25 (8) .
The stability of the GPGnlsLZ pseudotyped retrovirus and the TCRIPLacZ amphotropic retrovirus was determined in normal human serum. Twenty microliters virus harvest, which was diluted 1:5 in 20 mM Hepes buffer (pH 7.0), 10 ,ul of PBS, or 10 ,ul of Gal(al-3)galactose (final concentration, 10 mg/ml) (Dextra Laboratories, Reading, U.K.), and 20 ,ul of fresh normal human serum, heat-inactivated human serum, or IFS were mixed on ice and then incubated at 37°C for 1 h (26). Heat inactivation of the human serum was carried out at 56°C for 1 h. The virus-serum mixture was diluted in 1.5 ml DMEM with 8 ,ug/ml polybrene. Serial dilutions of the virus-serum mixture were incubated with NIH 3T3 cells in 6-well dishes as described above to determine viral titers. Relative titers (percent) were determined for fresh and heat-inactivated human serum treatment as compared with IFS treatment.
Helper Virus Assay. Retroviral stocks were assayed for replication-competent virus (RCV) by a vector rescue assay (27) (31) (32) (33) . In addition, retrovirus vectors produced from human cells have been shown to be resistant to the mechanisms of virus inactivation involving natural antibodies and complement that occur when virus derived from murine cells is exposed to human serum (2, 4) . Finally, 293 cells can be transiently transfected at high efficiency, a property potentially useful for generating small quantities of high titer virus in a rapid fashion (22) .
Because the high-level constitutive expression of VSV-G is toxic to cells, we employed the tetracycline-regulatable gene expression system of Gossen and Bujard (12) to provide for the inducible expression of VSV-G. The expression construct used to express the VSV-G protein, pMDtet.G (Fig. 1) (19) . AU3nlsLacZ encodes a nuclear localizing f3-galactosidase under the control of the HCMV enhancer-promoter. intervening sequence and poly(A) site from the human f3-globin gene. For expression of the tet/VP16 transactivator (12), we used the vector pBC.tTA, which utilizes the full CMV IE promoter and an intervening sequence and poly(A) signal from the rat insulin II gene (Fig. 1) . The tet/VP16 transactivator binds to the tet operator sequences in the promoter region of pMDtet.G and activates transcription of VSV-G from the minimal CMV promoter (12) . Transcription is suppressed in the presence of tetracycline and is activated when tetracycline is removed from the media.
For expression of the MuMLV gag-pol sequences, we used the expression vector pMD, which employs the CMV IE promoter and an intervening sequence and poly(A) site from the human 13-globin gene for expression of inserted sequences (Fig. 1) . Notably, this vector contains no retroviral sequences. A segment of the MuMLV genome that precisely encodes gag-pol was then inserted into the vector (see Fig. 1 ). These design features help to minimize the overlap of sequences between different vectors and the packaging cell sequences that can often occur, and which have been previously shown to contribute to the formation of RCV (34, 35) In comparison to pCRIPenv-, the construct used in the generation of TCRIP cells (15) , pMD.gagpol generated significantly higher levels of RT activity during transient transfection of 293 cells (data not shown).
The overall scheme for generating the 293GPG packaging cells is shown in Fig. 2 . The first step in the generation of the cells was the isolation of a 293-derived cell line that expressed VSV-G. Rather than sequentially introduce the pMDtet.G and pBC.tTA constructs into cells, we chose to simultaneously introduce both constructs via a tripartite cotransfection with a selectable marker in the hopes of providing a natural selection for integrants that express an acceptable level of VSV-G in the repressed state. Having identified a clone of cells that express high levels of VSV-G in the absence of tetracycline and low basal levels in the presence of tetracycline, the pMD.gagpol vector was then introduced by cotransfection into the cells. Candidate packaging cell lines were then screened for high RT levels in the media as described below.
Proc. Natl. Acad. Sci. USA 93 (1996) Proc. Natl. Acad. Sci. USA 93 (1996) (Fig. 1) and with a plasmid encoding resistance to puromycin as a selectable marker. The pBC.tTAand pMDtet.G-transfected cells were then cultured in media containing puromycin and 1 ,g/ml tetracyline during selection (to prevent expression of the VSV-G). Seventy-two independent drug-resistant clones were subsequently isolated and screened by removal of tetracycline from the growth medium. Western blot analysis identified 12 clones that exhibited high levels of VSV-G expression in the absence of tetracycline, yet low or no detectable VSV-G expression in the presence of tetracycline (data not shown). The 293 clone chosen for further study, termed 293G, demonstrated particularly high levels of VSV-G expression per mg of cellular protein, comparable to twice the amount of VSV-G expressed after transient transfection with pMD.G (Fig. 3A) . The two VSV-G bands detected in de-repressed 293G cells (Fig. 3A, lane 3) represent the completely glycosylated (upper band) and an incompletely glycosylated (lower band) form of VSV-G. Treatment of the postnuclear cellular lysate from the 293G cells with Nglycosidase F demonstrates a single unglycosylated VSV-G band (Fig. 3A, lane 9) . The observation of incomplete glycosylation of VSV-G in the 293G cells suggests that the extremely high level of expression of VSV-G may overwhelm the capacity of the cells for glycosylation or that the large quantity of VSV-G protein may stimulate intracellular recycling with deglycosylation (36) .
The high-level expression of VSV-G observed after transfection with the VSV-G expression constructs was consistently associated with significant morphologic changes in the cells. In transiently transfected 293 cells (data not shown) and in derepressed 293G cells, we observed formation of large multinucleated syncytia of cells, the appearance of which correlated precisely with VSV-G expression (Fig. 3B) . The VSV-G protein has a putative fusagenic domain spanning amino acids 123 to 137 (37) , which facilitates fusion between the membrane of the enveloped virus and the plasma membrane of target cell. The high-level cell surface expression of VSV-G in our transient and stable cell lines may promote fusion of plasma membranes of adjacent cells in response to local pH changes (38) .
Construction of a Packaging Cell Line Which Expresses Both VSV-G and MuMLVgag-pol. To generate a stable cell line which expresses both VSV-G and gag-pol, pMD.gagpol was linearized at the Scal site and introduced into 293G cells along with a plasmid encoding resistance to neomycin, using calcium phosphate transfection techniques. Sixty-nine G418-resistant clones (15) were isolated, and each culture supernatant was screened for the level of RT activity. Twenty-four positive clones with RT activity equivalent to or greater than that of TCRE (15) were identified on an initial screen (data not shown). The clone selected for further study, 293GPG, released -25-fold more RT activity than that released by TCRE and TCRIP (15) and -10-fold more activity than that released by Anjou 65 cells (22) (Fig. 4) . Removal blot analysis (Fig. 3A) and by the formation of syncytia (Fig.  3B) .
Production and Characteristics of Recombinant Virus from 293GPG Cells. To examine the capacity of the 293GPG cells to produce high titers of recombinant retrovirus vectors, the cells were cotransfected with the retroviral vector MFG.-SnlsLacZ, linearized by AseI, and a plasmid encoding resistance to zeocin (16) . Sixteen independent drug-resistant clones were isolated. The clones were then cultured in tetracyclinefree media and the supernatants were harvested at 96 h and were used to infect NIH 3T3 cells for determination of viral titer by 5-bromo-4-chloro-3-indolyl 13-D-galactoside (X-Gal) staining. Three of the clones, termed GPGnlsLZ2, GPGnlsLZ3, and GPGnlsLZ4, generated virus with titers of _107 colony forming units (cfu)/ml. To further determine the optimal time for virus harvest after removal of tetracycline, supernatants from the three previously selected clones were collected serially at successive time points (Fig. 5) . Maximal virus production per 24-h period was shown to occur between 48 and 96 h after removal of tetracycline.
Because 293 cells have been shown to yield efficient transient gene expression after transfection (22) , we next examined (39), which indicated the high transcriptional activity of the CMV IE promoter after transient transfection of 293 cells, we generated a derivative of MFG.S, termed AU3nlslLacZ, in which the enhancerpromoter region of the 5' long-terminal repeat was replaced with the complete CMV IE promoter in such a way that transcription would initiate at the proper viral start site (Fig.  1) . Using this construct in conjunction with lipofectamine transfection, we were able to obtain an average efficiency of transfection of the 293GPG cells of 40%. More importantly, when virus was harvested 24-72 h after transfection, titers exceeding 106 cfu/ml were obtained (Table 1) .
To determine whether virus produced from 293GPG cells could be efficiently concentrated, a large amount of culture supernatant was generated from the GPGnlsLZ2 and GPGnlsLZ3 clones. The pseudotyped virus, initially possessing titers of 1.6 x 106 cfu/ml, could be concentrated by ultracentrifugation > 1000-fold to achieve titers of > 109 cfu/ml with 65-67% recovery of the infectious viral particles (Table 1) .
Virus produced from the GPGnlsLZ cell lines were examined for the presence of RCV using a sensitive assay involving a Mus dunni cell line which harbors a highly transmissible retroviral genome encoding LacZ (21) . Helper virus assays performed on unconcentrated viral supernatants as well as supernatants from transient transfections demonstrated that the retroviral stocks generated from the packaging cells were free of RCV (Table 1) . It was not possible to perform cocultivation-based helper virus assays on the 293GPG-derived producer cell lines, since cocultivation of the cells with the Mus dunni indicator cells led to extensive cell fusion (data not shown).
Finally, because retroviruses produced from human cells are known to be resistant to inactivation by human serum (2, 4), we investigated the extent to which the viral pseudotypes produced from the 293GPG packaging cell line were resistant to inactivation by serum. Amphotropic virus from a TCRIPLZ producer clone and pseudotyped virus from the GPGnlsLZ4 clone were incubated with human serum, and the relative titers of each virus stock were then determined. The titer of the amphotropic virus was reduced by -250-fold after incubation with human serum, but not after incubation with heat-inactivated human serum (Fig.  6) . In contrast, incubation of the VSV-G/retrovirus pseudotypes with human serum resulted in only a 5-fold reduction in titer. In light of the demonstrated role of natural human antibodies directed against proteins carrying Gal(al-3)galactose terminal carbohydrates in the virus inactivation process (3, 4), we next Time course of VSV-G pseudotyped virus production by GPGnlsLZ clones. Clones GPGnIsLZ2, GPGnlsLZ3, and GPGnlsLZ4 were grown to 95% confluence in 100-mm dishes in tetracycline (1 ,ug/ml). Cells were rinsed and placed in 5 ml growth media without tetracycline.
Supernatants were harvested and replaced with fresh media (no tetracycline) at 24 intervals. Supernatants were titered on NIH 3T3 cells. Titer is expressed as cfu/ml. Times indicate the period after tetracycline removal during which viral production was assessed.
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DISCUSSION
The 293GPG packaging cell (34, 35) and/or the practice of isolating clonal virus producing cell lines and screening the cell lines for helper. Nevertheless, several of the design features of the 293GPG packaging cell line may also provide at least some theoretical advantages over existing cell lines with regard to the possibility of release of RCV. One problem with all existing murine-based packaging cell lines is the presence of both endogenous retroviral DNA sequences (31, 33) and retroviral-like RNAs (44) that are efficiently packaged and transmitted to cells, and may contribute to the generation of helper virus under certain conditions. Another issue relates to the potential of different packaging cell lines to give rise to helper virus due to the overlap of sequences between the particular vector used and the precise packaging sequences present in the packaging cell line (34, 35) . A more global inherent defect in the design of all murine and humanderived packaging cell lines is the ability of retroviral RNAs which lack packaging sequences to be packaged, albeit at low efficiency, and transmitted to cells (40) . Even in the case of third generation packaging cells (15) 
